BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10997966)

  • 1. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
    Br J Haematol; 2000 Sep; 110(3):573-6. PubMed ID: 10997966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
    J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
    Olsson-Strömberg U; Simonsson B; Ahlgren T; Björkholm M; Carlsson K; Gahrton G; Hast R; Löfvenberg E; Linder O; Ljungman P; Malm C; Paul C; Rödjer S; Turesson I; Udén AM; Wahlin A; Killander A; Wadman B; Westin J; Vikrot O; Zettervall O; Oberg G;
    Hematol J; 2004; 5(6):462-6. PubMed ID: 15570285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
    Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
    Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
    Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
    Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
    Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
    Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress with interferon in CML--results of the MRC UK CML III study.
    Shepherd PC; Richards SM; Allan NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
    Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
    Allan NC; Richards SM; Shepherd PC
    Lancet; 1995 Jun; 345(8962):1392-7. PubMed ID: 7760609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
    Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
    Hasford J; Baccarani M; Hehlmann R; Anseri H; Tura S; Zuffa E
    Blood; 1996 Jun; 87(12):5384-91. PubMed ID: 8652857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 16. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.